Fc-enhanced anti-CTLA-4 antibody, AGEN1181: new mechanistic insights for potent antitumor immunity and combination potential in treatment-resistant solid tumors.

被引：0
|
作者：
Tanne, Antoine J. [1 ]
Galand, Claire [1 ]
Abou-Slaybi, Abdo [1 ]
Wilkens, Margaret [1 ]
Marques, Marilyn [1 ]
Ng, Serina [2 ]
Han, Haiyong [2 ]
Dietrich, Sylvia [1 ]
Waight, Jeremy [1 ]
Joshi, Bishnu [1 ]
Yigit, Burcu [1 ]
Michelet, Xavier [1 ]
Levey, Daniel [1 ]
Savitsky, David [1 ]
Buell, Jennifer [1 ]
Chand, Dhan [1 ]
机构：
[1] Agenus Inc, Lexington, MA USA
[2] Translat Genom Res Inst TGen, Phoenix, AZ USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1878
引用
收藏
页数：2
相关论文
共 6 条
  • [1] AGEN1181, AN FC-ENHANCED ANTI-CTLA-4 ANTIBODY, ALONE AND IN COMBINATION WITH BALSTILIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS: INITIAL PHASE I RESULTS
    El-Khoueiry, Anthony
    Bullock, Andrea
    Tsimberidou, Apostolia
    Mahadevan, Daruka
    Wilky, Breelyn
    Twardowski, Przemyslaw
    Bockorny, Bruno
    Moser, Justin
    Feliu, Waldo Ortuzar
    Grossman, Joseph
    Rosenthal, Katherine
    O'Day, Steven
    Gordon, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A509 - A509
  • [2] Characterization of the pharmacodynamic activity of AGEN1181, an Fc-enhanced CTLA-4 antibody, alone and in combination with the PD-1 antibody balstilimab.
    Shapiro, Irina
    Lim, Min
    Pabla, Simarjot
    O'Day, Steven J.
    El-Khoueiry, Anthony
    Ramamurthy, Chethan
    Bullock, Andrea J.
    Gordon, Michael S.
    Buell, Jennifer
    Chand, Dhan
    Wijatyk, Anna
    CANCER RESEARCH, 2021, 81 (13)
  • [3] AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody with improved therapeutic potential for the treatment of patients with advanced malignancies.
    O'Day, Steven
    Ramamurthy, Chethan
    Bullock, Andrea J.
    El-Khoueiry, Anthony B.
    Ohanjanian, Lernik
    Wijatyk, Anna
    Feliu, Waldo Ignacio Ortuzar
    Shapiro, Irina
    Ancukiewicz, Marek
    Chand, Dhan
    Buell, Jennifer
    Gordon, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] AGEN1181, AN FC ENGINEERED ANTI-CTLA-4 ANTIBODY, DEMONSTRATES CLINICAL ACTIVITY, ALONE OR IN COMBINATION WITH BALSTILIMAB (ANTI-PD-1), AND BROADENS THE THERAPEUTIC POTENTIAL OF CTLA-4 THERAPY
    O'Day, Steven
    El Khoueiry, Anthony
    Ramamurthy, Chethan
    Bullock, Andrea
    Shapiro, Irina
    Serina
    Han, Haiyong
    Namagerdi, Lernik Ohanjanian
    Kaleta, Remigiusz
    Wijatyk, Anna
    Wijatyk, Olivia
    Ortuzar, Waldo
    Ancukiewicz, Marek
    Buell, Jennifer
    Chand, Dhan
    Gordon, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A242 - A242
  • [5] Preclinical functional characterization of AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody for the treatment of patients with early and advanced malignancies.
    Waight, Jeremy
    Manrique, Mariana
    Gombos, Randi
    Costa, Matthew
    Iyer, Priyadarshini
    Vincent, Sylvia
    Ward, Rebecca
    Paltrinieri, Elena
    Chand, Dhan
    Wilson, Nicholas
    Buell, Jennifer
    Savitsky, David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Phase 1/2 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC.
    Hecht, Joel R.
    Davar, Diwakar
    Fakih, Marwan
    Bekaii-Saab, Tanios S.
    Devito, Nicholas C.
    Knecht, John George
    Vandross, Andrae Lavon
    Perez, Cesar Augusto
    Bessudo, Alberto
    Gupta, Anurag
    Patel, Ekta
    Fantini, Damiano
    Paramasivan, Sattanathan
    Crowe, David
    Duncan, Meghan
    McConnell, Scott
    Luptakova, Katarina
    Parikh, Aparna Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 206 - 206
1